Nanogrow develops therapies based on nanobodies, a class of camelid-derived nanoantibodies noted for smaller size, stability, and tissue penetration. The company is focused on therapeutic applications in oncology and immune-related diseases. It is headquartered in Uruguay and is pursuing expansion into European markets. Nanogrow is currently advancing a $5 million seed round to continue development of its technology and to support research and development activities. The article emphasizes the startup’s role in translating advanced biotechnology from the region into globally competitive programs. No revenue, user, or prior funding metrics were reported in the article.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026